IL15 and T-cell leukemia: First evidence of the leukemogenic effects of IL-15 was described in 1994 in HTLV1-associated human T cell leukemia, where IL-15 levels were highly increased and anti-CD122 monoclonal antibody treatment reduced leukemic cell growth [95,96].